University of Cambridge

Responsible AI Institute Marks Q4 2023 with New Members and 400% Yearly Growth

Retrieved on: 
Wednesday, January 17, 2024
Advocacy Group Opinion, Manufacturing, Other Philanthropy, Software, Artificial Intelligence, Consulting, Environmental, Social and Governance (ESG), Social Activism, Professional Services, Philanthropy, Technology, Public Policy, Government, Data Analytics, Communications, Continuing, Engineering, Training, Education, Risk management, University, ISO, OECD, Trust, Policy, Multimedia, Documentation, Safety, Consortium, NIST, ESG, Ecosystem, Booz Allen Hamilton, Generative, Acquisition, Hallucination, Standards New Zealand, Trust (social science), Organization, Human, RAI, Responsibility, University of Cambridge, Growth, Medical device

Responsible AI Institute (RAI Institute), a prominent non-profit organization dedicated to facilitating the responsible use of AI worldwide, has announced that Booz Allen and Spark92 have joined the Institute as members.

Key Points: 
  • Responsible AI Institute (RAI Institute), a prominent non-profit organization dedicated to facilitating the responsible use of AI worldwide, has announced that Booz Allen and Spark92 have joined the Institute as members.
  • View the full release here: https://www.businesswire.com/news/home/20240117590446/en/
    Responsible AI Institute's Q4 2023 New Members (Graphic: Responsible AI Institute)
    "In 2023, we made substantial progress in expanding our global influence in responsible AI adoption and we're delighted to welcome Booz Allen and Spark92 as our newest members," stated Manoj Saxena, founder and executive chairman of Responsible AI Institute.
  • RAI Institute members gain exclusive access to:
    Valuable resources: Members have access to a range of tools and resources through RAI Institute’s Responsible AI testbed.
  • Contribution to responsible AI ecosystem: Engagement with RAI Institute not only demonstrates an organization’s commitment to ethical AI practices to their stakeholders but also actively contributes to shaping a responsible AI ecosystem, influencing global standards in AI governance and innovation.

Summer Discovery Unveils Exciting New Lineup for Pre-College & Gifted Students in 2024

Retrieved on: 
Tuesday, January 23, 2024
Graduate, Student, Summer Discovery, Learning, Humanities, University of Michigan, Aesthetics, Real Madrid CF, STEM, Context, Partnership, Digital transformation, Tuck School of Business, Discovery, Ivy League, Curriculum, Business, University, Medicine, Health geography, ChatGPT, Entrepreneurship, Geisel School of Medicine, UCLA, Ethics, Psychology, University of Cambridge, Parent, Thayer School of Engineering, Data science, Education, Introduction, Growth, Management

ROSLYN, N.Y., Jan. 23, 2024 /PRNewswire/ -- Summer Discovery, the global leader in pre-college programs for nearly six decades, announces its highly-anticipated program and university campus lineup for the summer of 2024. With more university campus and date options, new academic and career-focused programs, and an extensive selection of immersive hands-on courses spanning many subjects and disciplines, Summer Discovery continues to lead the way in providing unparalleled summer educational experiences that prepare students for success both in the classroom and in preparation for college.

Key Points: 
  • Summer Discovery announces its pre-college program and university campus lineup for the summer of 2024.
  • "The 2024 lineup reflects our dedication to fostering transformative summer programs and experiences to students around the world."
  • For nearly six decades, parents have trusted Summer Discovery to provide a safe, enriching summer experience for their children.
  • As the new year unfolds, Summer Discovery encourages families to plan ahead for a summer brimming with exploration, learning, and growth.

Global Lithium-Sulfur Battery Industry Report 2023-2028 Featuring Prominent Players - PolyPlus Battery, NexTech, Li-S Energy Lyten,, Zeta Energy, Theion, Gelion, Hybrid Kinetic, and ADEKA

Retrieved on: 
Friday, January 12, 2024
Lithium, Aerospace, Research, Component, Density, Electronics, Cathode, USD, Tablet, Region, University of Cambridge, Growth, Electric battery

A lithium-sulfur (Li-S) battery is a type of rechargeable battery that employs lithium as the anode and sulfur as the cathode.

Key Points: 
  • A lithium-sulfur (Li-S) battery is a type of rechargeable battery that employs lithium as the anode and sulfur as the cathode.
  • Lithium-sulfur batteries are known for their high theoretical energy density, making them a promising candidate for next-generation energy storage systems.
  • Further the governmental support to the battery companies will accelerate the growth of lithium-sulfur battery market in the region.
  • Cambridge University Conducts R&D to Improve Specific Energy, Safety, and Mass Density of Li-S Batteries

Medical Education Market size to grow by USD 208.73 billion from 2022 to 2027, Market is fragmented due to the presence of prominent companies like All India Institute of Medical Sciences, KP Bernard J. Tyson School of Medicine and Mayo Clinic, and many m

Retrieved on: 
Friday, January 5, 2024
University of Eastern Finland, Yale University, Geography, University of Liverpool, TTUHSC, Learning, University of Oxford, National university, National University of Singapore, University of Washington, University of California, University of New England, Johns Hopkins University, Education, Stanford University, Western Governors University, USD, University, Knowledge, Mayo Clinic, Growth, University of Cambridge, Grand Canyon University, Harvard Medical School, University of Alabama, Nursing

The medical education market is fragmented owing to the presence of many global and regional companies.

Key Points: 
  • The medical education market is fragmented owing to the presence of many global and regional companies.
  • Download a Sample before buying
    KP Bernard J. Tyson School of Medicine - The company offers medical education such as a Bachelor of Science (BS) in Health Sciences.
  • National University of Singapore - The company offers medical education such as M.D.M.B.A., M.D.Ph.D., M.D.M.P.H., and M.D.MSHCM, and others.
  • The higher education testing and assessment market is estimated to grow at a CAGR of 6.32% between 2022 and 2027.

Frazier Life Sciences Strengthens Investment Team with Addition of Lin Mu, M.D., MBA as Senior Associate

Retrieved on: 
Thursday, January 4, 2024
Yale University, Conference, Research, Economics, Denison University, Science, MBA, University, PALO, Medicine, Growth, University of Cambridge, FLS, Epidemiology

PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Frazier Life Sciences (FLS), a longstanding venture capital firm investing in innovative biopharmaceuticals, proudly welcomes Lin Mu, M.D., MBA as a senior associate based in the Palo Alto office to its team of investment professionals.

Key Points: 
  • PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Frazier Life Sciences (FLS), a longstanding venture capital firm investing in innovative biopharmaceuticals, proudly welcomes Lin Mu, M.D., MBA as a senior associate based in the Palo Alto office to its team of investment professionals.
  • These valuable skills position him as a strong addition to FLS, enhancing the firm's capability to continue growing its venture investing.
  • "We believe Lin's background is ideally suited for our mission at Frazier Life Sciences.
  • "Lin will play an important role in supporting our continued efforts to grow and evolve the Frazier Life Sciences' investment strategies."

Educational Innovation Through AI: Cognizant Signs Multi-Year Contract with Cambridge University Press & Assessment

Retrieved on: 
Wednesday, January 3, 2024
Research, AI, University, Education, Learning, CTSH, Assessment, University of Cambridge

LONDON, Jan. 3, 2024 /PRNewswire/ -- Cambridge University Press & Assessment (Cambridge) has signed a multi-year contract with Cognizant (Nasdaq: CTSH) with the goal of improving operational effectiveness, maintaining exam results integrity and staying competitive in the evolving education sector. Under the agreement, Cognizant will continue to provide application development and support services to Cambridge.

Key Points: 
  • LONDON, Jan. 3, 2024 /PRNewswire/ -- Cambridge University Press & Assessment (Cambridge) has signed a multi-year contract with Cognizant (Nasdaq: CTSH) with the goal of improving operational effectiveness, maintaining exam results integrity and staying competitive in the evolving education sector.
  • In response to this demand, Cambridge and Cognizant will drive digital transformation, transition to a product-centric approach and leverage AI technology.
  • "We are delighted to be continuing our work with Cambridge University Press & Assessment to deliver an innovative digital approach to education," said Rohit Gupta, UK&I Managing Director at Cognizant.
  • "Cognizant is an excellent provider to support us with the next phase of our digital transformation," said Mark Maddocks, Chief Information Officer at Cambridge University Press & Assessment.

Educational Innovation Through AI: Cognizant Signs Multi-Year Contract with Cambridge University Press & Assessment

Retrieved on: 
Wednesday, January 3, 2024
Research, AI, University, Education, Learning, CTSH, Assessment, University of Cambridge

LONDON, Jan. 3, 2024 /PRNewswire/ -- Cambridge University Press & Assessment (Cambridge) has signed a multi-year contract with Cognizant (Nasdaq: CTSH) with the goal of improving operational effectiveness, maintaining exam results integrity and staying competitive in the evolving education sector. Under the agreement, Cognizant will continue to provide application development and support services to Cambridge.

Key Points: 
  • LONDON, Jan. 3, 2024 /PRNewswire/ -- Cambridge University Press & Assessment (Cambridge) has signed a multi-year contract with Cognizant (Nasdaq: CTSH) with the goal of improving operational effectiveness, maintaining exam results integrity and staying competitive in the evolving education sector.
  • In response to this demand, Cambridge and Cognizant will drive digital transformation, transition to a product-centric approach and leverage AI technology.
  • "We are delighted to be continuing our work with Cambridge University Press & Assessment to deliver an innovative digital approach to education," said Rohit Gupta, UK&I Managing Director at Cognizant.
  • "Cognizant is an excellent provider to support us with the next phase of our digital transformation," said Mark Maddocks, Chief Information Officer at Cambridge University Press & Assessment.

Fernando Mezzomo, CEO of Antidote, Announces their Platform Launch with Closed Community X on It

Retrieved on: 
Thursday, November 23, 2023
Heart, Rotary International, Marketing, Hobby, International, HKUST, Family, Intelligence, Social justice, University of Cambridge

NEW YORK, NY, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Today, Antidote founder and CEO Fernando Mezzomo unveiles the closed community "X", designed to give people equal access to profitable investment tools, and announced the official launch of the Antidote platform.

Key Points: 
  • NEW YORK, NY, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Today, Antidote founder and CEO Fernando Mezzomo unveiles the closed community "X", designed to give people equal access to profitable investment tools, and announced the official launch of the Antidote platform.
  • We created Antidote as an alternative for anyone who wants to achieve financial prosperity but is denied the opportunity," said Fernando.
  • The closed community X is organized so that almost anyone, regardless of social status or initial budget, can become a successful investor.
  • The company is actively building an international community of like-minded individuals who share the values of equal opportunity and social justice.

DeepMirror Launches Early Access Programme for Its Intuitive Molecular Drug Design Software

Retrieved on: 
Monday, December 11, 2023
University, Biotechnology, Education, Technology, Health, Pharmaceutical, Health Technology, Research, Software, Artificial Intelligence, Science, BCG, DMTA, Trust, Medicinal chemistry, ISCB Senior Scientist Award, University of Cambridge, Wellcome Trust, Entrepreneurship, Toxicity, Drug design, System, AI, ADME, Lead, Access, Medical device, Drug discovery

DeepMirror, a University of Cambridge spin-out company developing intuitive design software for the discovery of novel therapeutic drugs, today announced the launch of its Early Access Programme after a successful closed beta programme during which chemists were invited to test the software over several months.

Key Points: 
  • DeepMirror, a University of Cambridge spin-out company developing intuitive design software for the discovery of novel therapeutic drugs, today announced the launch of its Early Access Programme after a successful closed beta programme during which chemists were invited to test the software over several months.
  • The software allows users to tap into AI-driven insights to improve and accelerate molecular design across the drug discovery pipeline through a secure and user-friendly interface which makes AI-powered drug discovery as simple as using a spreadsheet.
  • AI-enabled drug discovery programmes often start with pharmaceutical companies partnering with AI companies to deliver insights for their drug discovery efforts.
  • After 12 months of development and a successful beta testing programme, we are excited to officially launch DeepMirror to early adopters.

Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02)

Retrieved on: 
Tuesday, December 5, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Principal, Safety, ANCA, Cirrhosis, Disease, Nephritis, RPGN, Clinical trial, Patient, Dialysis, CLDN1, Pharmacokinetics, University of Cambridge, Immunoglobulin A, Kidney, Diabetes, Trial of the century, Lupus, Aarhus University Hospital, Vasculitis, Pharmaceutical industry

The randomized, double-blind, placebo-controlled Phase 2 study ( NCT06047171 ) of lixudebart evaluates the drug’s safety, tolerability, pharmacokinetics, and how well it protects against the loss of kidney function.

Key Points: 
  • The randomized, double-blind, placebo-controlled Phase 2 study ( NCT06047171 ) of lixudebart evaluates the drug’s safety, tolerability, pharmacokinetics, and how well it protects against the loss of kidney function.
  • The study plans to recruit patients with Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis with Rapidly Progressive Glomerulonephritis (RPGN).
  • This disease typically causes a rapid and dramatic loss of kidney function and can result in kidney loss with patients requiring dialysis or a transplant.
  • It is the second clinical trial investigating lixudebart in patients after the initiation of a clinical study in advanced liver fibrosis patients earlier this year,” said Dr. Luigi Manenti, Chief Medical Officer of Alentis.